Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
With so many global regulation changes, staying informed is a challenge. Join other regulatory professionals as you navigate the gray together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Either RAC exam (Devices and Drugs) may be taken at any location. Find an upcoming exam at a location near you.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The RAPS store will be under maintenance Saturday, 29 February between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 12 May 2015 | By Michael Mezher
The European Medicines Agency (EMA) is launching a new initiative to monitor selected medical literature to proactively identify suspected adverse drug reactions (ADRs) for some 400 active substances.
Pharmacovigilance is the process of monitoring the use of drugs after they have entered the market. In particular, regulators, companies and healthcare providers are responsible for monitoring drugs and reporting suspected ADRs. This information is incredibly important to ensuring patient safety after a product has been approved.
The primary legal basis for pharmacovigilance requirements in the EU are found in Article 57 of Regulation (EC) No. 726/2004 and Title IX of Directive 2001/83/EC. In 2010 and 2012, the EU introduced new directives and regulations amending its pharmacovigilance requirements, which are collectively known as the new pharmacovigilance legislation.
Under Article 27 of Regulation (EU) No. 1235/2010, EMA is required to monitor the medical literature for ADRs:
"The Agency shall monitor selected medical literature for reports of suspected adverse reactions to medicinal products containing certain active substances. It shall publish the list of active substances being monitored and the medical literature subject to this monitoring."
The agency says this will "improve the safety monitoring of medicines by enhancing the quality and consistency of data" entered in the EudraVigilance database.
Beginning in July 2015, EMA will begin monitoring the selected medical literature for the first 50 substances it has identified. The agency expects to expand its monitoring operations to all 400 substances by September 2015.
The active substances EMA will be monitoring include many common active ingredients such as ibuprofen, diclofenac and lidocaine, and herbal ingredients such as echinacea and aloe.
EMA estimates that 4,000 companies will benefit from this service as they will not be required to monitor the selected publications for the active substances identified by the agency, though they will be required to monitor other medical literature for suspected ADRs relating to their products.
The agency has released a detailed guide, a chart of inclusion/exclusion criteria, as well as the full list (Excel) of monitored substances as part of its medical literature monitoring service.
EMA Press Release
Tags: ADR, Pharmacovigilance, Active Substances, Literature
Regulatory Focus newsletters
All the biggest regulatory news and happenings.